Early Diagnosis of Pancreatic Cancer by Nerve Growth Factor Receptor

Abstract

Pancreatic cancer in many cases can’t be detected until cancer has progressed and spread to other parts of the body. The cancer prognosis is subject to a great deal on the stage of the disease at the time of diagnosis. In this case-control study, the levels of truncated NGF receptor of a 54-year-old man diagnosed with metastatic adenocarcinoma were measured and compared with that of a healthy subject. NGFR levels were found in the urine samples collected from both patient and control subjects with significantly higher levels in the patients as compared to those of control subject This finding suggests that the urinary truncated NGF receptor has the competency to be taken as a molecular biomarker for prognosis of pancreatic cancer.